Company intelligence / Profile preview

nContact Surgical

Morrisville, North Carolina, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

nContact Surgical developed minimally invasive epicardial ablation devices for the treatment of atrial fibrillation and other cardiac arrhythmias. Its flagship products integrated suction, perfusion, and radiofrequency energy to create continuous biatrial lesions on the beating heart. The company received FDA clearance, CE Mark approval, raised $47.9M in funding, filed over two dozen patents, and was acquired by AtriCure in October 2015.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on nContact Surgical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nContact Surgical.

Explore the full profile